MREO Mereo Biopharma Group Plc ADR
$1.35 $0.00 (0.00%)
15 Minute Delayed Price Enable Real-Time Price
Overall
MREO Stock Analysis Overview
What this means: Mereo Biopharma Group Plc ADR (MREO) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 86 means that our comprehensive methodology rates Mereo Biopharma Group Plc ADR above 86% of stocks.
Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.
Fundamental PREMIUM
MREO Fundamental Analysis
Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.
Upgrade to Premium to unlock Fundamental Ranking
Short-Term Technical PREMIUM
MREO Short-Term Technical Analysis
Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.
Upgrade to Premium to unlock Short-Term Technical Ranking
Long-Term Technical PREMIUM
MREO Long-Term Technical Analysis
Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.
Upgrade to Premium to unlock Long-Term Technical Ranking
Analyst Ranking PREMIUM
MREO Analyst Ranking
Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.
Upgrade to Premium to unlock Analyst Ranking Analysis
Valuation PREMIUM
MREO Valuation Ranking Analysis
Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.
Upgrade to Premium to unlock Valuation Ranking
Stock Sentiment PREMIUM
MREO Stock Sentiment Analysis
Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.
Upgrade to Premium to unlock Stock Sentiment Ranking
MREO Stock Analysis Overview
What this means: Mereo Biopharma Group Plc ADR (MREO) gets a very positive evaluation from InvestorsObserver's ranking system. An Overall Rank of 86 means that our comprehensive methodology rates Mereo Biopharma Group Plc ADR above 86% of stocks.
Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.
Create a FREE account to see full MREO report
MREO Fundamental Analysis
Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.
Upgrade to Premium to unlock Fundamental Ranking
MREO Short-Term Technical Analysis
Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.
Upgrade to Premium to unlock Short-Term Technical Ranking
MREO Long-Term Technical Analysis
Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.
Upgrade to Premium to unlock Long-Term Technical Ranking
MREO Analyst Ranking
Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.
Upgrade to Premium to unlock Analyst Ranking Analysis
MREO Valuation Ranking Analysis
Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.
Upgrade to Premium to unlock Valuation Ranking
MREO Stock Sentiment Analysis
Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.